PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33784336-15 2021 CONCLUSION: Vitamin B12 deficiency and diabetic neuropathy are very high among metformin-treated T2DM patients and it is associated with increased GPA, IFA, TNF-alpha and cardiometabolic risk factors (higher LDL and TC and lower HDL). Metformin 79-88 tumor necrosis factor Homo sapiens 157-166 33444083-8 2021 We observed that participants on 3000 mg/day dose of metformin had significantly lower levels of TNF-alpha (p < .001) and IFN-gamma (p = .014) compared to those on other dosages (1000 mg and 2000 mg/day). Metformin 53-62 tumor necrosis factor Homo sapiens 97-106 33444083-10 2021 After adjusting for age, gender, dose and duration of metformin use, we observed that participants who took higher doses of metformin had significantly reduced levels of TNF-alpha (beta = -0.0297, 95% CI = (-0.005 to -0.002) p < .001. Metformin 54-63 tumor necrosis factor Homo sapiens 170-179 33444083-10 2021 After adjusting for age, gender, dose and duration of metformin use, we observed that participants who took higher doses of metformin had significantly reduced levels of TNF-alpha (beta = -0.0297, 95% CI = (-0.005 to -0.002) p < .001. Metformin 124-133 tumor necrosis factor Homo sapiens 170-179 33444083-11 2021 Metformin dosage independently predicted reduced TNF-alpha levels with 14.4% variations in the metformin dosage levels. Metformin 0-9 tumor necrosis factor Homo sapiens 49-58 33444083-12 2021 Increased metformin dosage suppresses TNF-alpha levels in systemic circulation and hence might contribute to its beneficial effects. Metformin 10-19 tumor necrosis factor Homo sapiens 38-47 33580540-2 2021 Metformin is known to decrease interleukin-6 (IL-6) and tumor-necrosis alpha (TNFalpha), which appear to contribute to morbidity in COVID-19. Metformin 0-9 tumor necrosis factor Homo sapiens 78-86 33141769-0 2021 Metformin Inhibits Transforming Growth Factor beta-Induced Fibrogenic Response of Human Dermal Fibroblasts and Suppresses Fibrosis in Keloid Spheroids. Metformin 0-9 tumor necrosis factor Homo sapiens 19-50 33017649-8 2021 Cumulative evidence from these RCTs supported the blood glucose lowering effects of metformin, in addition to promoting weight loss, ameliorating insulin resistance, and reducing pro-inflammatory markers such as interleukin-6 and tumor necrosis factor-alpha in patients with metabolic syndrome. Metformin 84-93 tumor necrosis factor Homo sapiens 230-257 33517358-8 2021 Metformin, thalidomide and cytokines (IFN, tumor necrosis factor (TNF), interleukin-2 (IL-2) and others) have pleiomorphic activities, some of which can enhance tumorigenesis. Metformin 0-9 tumor necrosis factor Homo sapiens 43-64 33517358-8 2021 Metformin, thalidomide and cytokines (IFN, tumor necrosis factor (TNF), interleukin-2 (IL-2) and others) have pleiomorphic activities, some of which can enhance tumorigenesis. Metformin 0-9 tumor necrosis factor Homo sapiens 66-69 32646922-11 2020 In both humans and mice, metformin triggered AMPK activation and STAT3 inactivation, and altered the production of effector cytokines (i.e. TNF-alpha, IFN-gamma, IL-10) in the immune cells. Metformin 25-34 tumor necrosis factor Homo sapiens 140-149 32516360-10 2020 Of note, either nicotine treatment or activation of AMPK by intracerebroventricular infusion of metformin reduced LPS-induced impairment of fear memory reconsolidation, and ameliorated inflammation factor TNF-alpha and IL-1beta as well as the expression of CRTC1. Metformin 96-105 tumor necrosis factor Homo sapiens 205-214 32967076-5 2020 Patients treated with metformin showed decreased levels of all analyzed serum pro-inflammatory markers (TNFalpha, IL6, IL1beta and MCP1) and a downwards trend in IL18 levels associated with a lower production of oxidative stress markers in leukocytes (mitochondrial ROS and myeloperoxidase (MPO)). Metformin 22-31 tumor necrosis factor Homo sapiens 104-112 32607520-13 2020 This sex-specific finding is consistent with metformin reducing TNF-alpha in females over males, and suggests that metformin conveys protection in Covid-19 through TNF-alpha effects. Metformin 45-54 tumor necrosis factor Homo sapiens 64-73 32828146-8 2021 Metformin has been used to evaluate their potential modulatory effects on cells treated with TNF-alpha. Metformin 0-9 tumor necrosis factor Homo sapiens 93-102 32828146-11 2021 The TNF-alpha-induced expression of inflammatory cytokines and protease and growth factor genes in MH7A cells was downregulated by metformin. Metformin 131-140 tumor necrosis factor Homo sapiens 4-13 32801814-9 2020 A combination of drugs showed that the expression of TNF-alpha was almost the same as for metformin alone. Metformin 90-99 tumor necrosis factor Homo sapiens 53-62 32607520-13 2020 This sex-specific finding is consistent with metformin reducing TNF-alpha in females over males, and suggests that metformin conveys protection in Covid-19 through TNF-alpha effects. Metformin 115-124 tumor necrosis factor Homo sapiens 164-173 32207597-0 2021 Study of effect of metformin on expression levels of TNF-alpha and IL-18 in animal models of polycystic ovary syndrome. Metformin 19-28 tumor necrosis factor Homo sapiens 53-62 32518807-9 2020 After metformin treatment, expression of interleukin 6 (IL-6), TNF-alpha, and IL-1beta were significantly downregulated in RA-FLSs; however, increased expression of p-AMPK-alpha1, protein kinase A (PKA)-alpha1, and HAPLN1 (hyaluronan and proteoglycan link protein 1) was observed. Metformin 6-15 tumor necrosis factor Homo sapiens 63-72 32452405-11 2020 DISCUSSION: Low dose combination metformin and sulfasalazine reduced cytotrophoblast sFlt-1 and sENG secretion, increased VEGFalpha expression and reduced TNFalpha induced endothelin-1 expression in primary endothelial cells. Metformin 33-42 tumor necrosis factor Homo sapiens 155-163 32194991-6 2020 To further reveal the mechanism involved, we examined how metformin treatment affected NLRP3 inflammasome activated by TNF-alpha and IL-17A stimulation. Metformin 58-67 tumor necrosis factor Homo sapiens 119-128 32194991-10 2020 Metformin treatment inhibited upregulation of IL-36gamma, CXCL1, CXCL2, CCL20, S100A7, S100A8 and S100A9 mRNA and protein levels induced by TNF-alpha and IL-17A stimulation. Metformin 0-9 tumor necrosis factor Homo sapiens 140-149 32769032-8 2020 RESULTS: Metformin showed maximum percent declined from baseline to three months therapy in levels of fructosamine, beta-amyloid, sRAGE, inflammatory cytokines (IL-6, TNF-alpha) and percent increment in esRAGE and antioxidants levels. Metformin 9-18 tumor necrosis factor Homo sapiens 167-176 31442575-7 2019 Metformin and Liraglutide were shown to elicit significantly greater release of TNFa, IL-6, and GM-CSF, while Sitagliptin had a lesser effect on pro-inflammatory cytokine production. Metformin 0-9 tumor necrosis factor Homo sapiens 80-84 30959417-8 2019 Treatment of insulin resistant cells with SF or metformin alone decreased levels of reactive oxygen species (ROS), malondialdehyde (MDA), tumor necrosis factor (TNF-alpha) and interleukin-6 (IL-6); whereas antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) activity, as well as total antioxidant capacity (T-AOC) ability increased. Metformin 48-57 tumor necrosis factor Homo sapiens 138-159 31326727-12 2019 The combination of liraglutide and metformin reduced the total LDL subfractions, primarily by reducing the most atherogenic subfraction LDL5, and reduced CRP but not TNF-alpha. Metformin 35-44 tumor necrosis factor Homo sapiens 166-175 30959417-8 2019 Treatment of insulin resistant cells with SF or metformin alone decreased levels of reactive oxygen species (ROS), malondialdehyde (MDA), tumor necrosis factor (TNF-alpha) and interleukin-6 (IL-6); whereas antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) activity, as well as total antioxidant capacity (T-AOC) ability increased. Metformin 48-57 tumor necrosis factor Homo sapiens 161-170 30334569-5 2019 Metformin also significantly ( p < 0.05) inhibited TAA-induced HIF-1alpha, mTOR, the profibrogenic biomarker alpha-smooth muscle actin, tissue inhibitor of metalloproteinases-1, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), alanine aminotransferase (ALT) and aspartate aminotransferase in harvested liver homogenates and blood samples. Metformin 0-9 tumor necrosis factor Homo sapiens 178-205 30753544-6 2019 At a functional level, metformin lowered ex vivo production of tumor necrosis factor alpha, interferon gamma, and interleukin 1beta but increased phagocytosis activity and reactive oxygen species production. Metformin 23-32 tumor necrosis factor Homo sapiens 63-90 30334569-5 2019 Metformin also significantly ( p < 0.05) inhibited TAA-induced HIF-1alpha, mTOR, the profibrogenic biomarker alpha-smooth muscle actin, tissue inhibitor of metalloproteinases-1, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), alanine aminotransferase (ALT) and aspartate aminotransferase in harvested liver homogenates and blood samples. Metformin 0-9 tumor necrosis factor Homo sapiens 207-216 31178745-11 2019 We also show that metformin monotherapy was associated with significantly lower levels of inflammatory molecules, like TNFalpha, sTNFRI, and sTNFRII, when compared to other monotherapies. Metformin 18-27 tumor necrosis factor Homo sapiens 119-127 30628691-10 2019 Furthermore, it was confirmed that metformin suppressed the LPS-induced secretion of TNF-alpha, IL-6, ICAM-1 and VCAM-1. Metformin 35-44 tumor necrosis factor Homo sapiens 85-94 30890498-10 2019 The results of ELISA and qRT-PCR revealed that metformin treatment obviously increased Foxp3 and TGF-beta expressions at both the protein and mRNA levels and significantly decreased the levels of ROR-gammat, IL-17 and TNF-alpha as well as IL-35 level in these patients. Metformin 47-56 tumor necrosis factor Homo sapiens 218-227 30097812-4 2018 We examined the influence of hyperglycemia (25 mmol/L glucose; HG group; N = 36) on metformin-mediated effects on CX3CL1 and TNF-alpha production by placental lobules perfused extracorporeally. Metformin 84-93 tumor necrosis factor Homo sapiens 125-134 30520054-4 2019 Our results demonstrated that metformin significantly decreased the mRNA and protein levels of tumour necrosis factor-alpha (TNFalpha), interleukin (IL)-6, IL-8, and IL-1beta induced by TNFalpha. Metformin 30-39 tumor necrosis factor Homo sapiens 125-133 30520054-4 2019 Our results demonstrated that metformin significantly decreased the mRNA and protein levels of tumour necrosis factor-alpha (TNFalpha), interleukin (IL)-6, IL-8, and IL-1beta induced by TNFalpha. Metformin 30-39 tumor necrosis factor Homo sapiens 186-194 30097812-7 2018 Metformin (2.5 and 5.0 mg/L; subgroups B and C) lowered the production of CX3CL1 and TNF-alpha in a dose-dependent and time-dependent manner. Metformin 0-9 tumor necrosis factor Homo sapiens 85-94 29383869-8 2018 While each tissue had a signature reflecting its own function, we identified a cascade of predictive upstream transcriptional regulators, including mTORC1, MYC, TNF, TGFss1, and miRNA-29b that may explain tissue-specific transcriptomic changes in response to metformin treatment. Metformin 259-268 tumor necrosis factor Homo sapiens 161-164 29221717-6 2018 TNFalpha plasma levels were decreased significantly vs. baseline by metformin combined with TLC intervention (-22.90+-46.76%, P=0.01). Metformin 68-77 tumor necrosis factor Homo sapiens 0-8 29513760-6 2018 Several inflammatory molecules upregulated by tumor necrosis factor-alpha in human retinal vascular endothelial cells were markedly reduced by metformin, including nuclear factor kappa B p65 (NFkappaB p65), intercellular adhesion molecule-1 (ICAM-1), monocyte chemotactic protein-1 (MCP-1), and interleukin-8 (IL-8). Metformin 143-152 tumor necrosis factor Homo sapiens 46-73 28337819-8 2017 Moreover, insulin-sensitizing drugs (metformin, pioglitazone, and rosiglitazone) suppress LPS-induced TGF-beta and TNF-alpha mRNA expression in PFMC. Metformin 37-46 tumor necrosis factor Homo sapiens 115-124 28699677-8 2017 Also, our in vitro study showed that metformin inhibited TNF-alpha-induced MMP-9 up-regulation in neutrophils, which might be mediated via an AMPK-dependent pathway. Metformin 37-46 tumor necrosis factor Homo sapiens 57-66 29466360-8 2018 We examined the ability of metformin + esomeprazole to rescue TNF-alpha induced vascular cell adhesion molecule-1 (VCAM-1) and Endothelin-1 (ET-1) expression, leukocyte adhesion (markers of endothelial dysfunction). Metformin 27-36 tumor necrosis factor Homo sapiens 62-71 29466360-11 2018 The low-dose combination of metformin + esomeprazole additively reduced TNF-alpha-induced VCAM-1 mRNA, but not VCAM-1 protein expression. Metformin 28-37 tumor necrosis factor Homo sapiens 72-81 33385166-4 2018 Metformin has been shown to inhibit the effects of tumor necrosis factor (TNF)-alpha. Metformin 0-9 tumor necrosis factor Homo sapiens 51-84 29148173-6 2018 We found that metformin ameliorated the induction of colitis and reduced the levels of pro-inflammatory cytokines IL-6, TNF-a and IL-1beta. Metformin 14-23 tumor necrosis factor Homo sapiens 120-125 29228440-7 2017 RESULTS: Metformin attenuates the effects of TNF-alpha on Caco-2 cell TEER and paracellular permeability, prevents TNF-alpha-induced morphological disruption of tight junctions, ameliorates the inhibiting effect of TNF-alpha on epithelial tight junction-related protein expression and suppresses the TNF-alpha-induced increase in MLCK production. Metformin 9-18 tumor necrosis factor Homo sapiens 45-54 29228440-7 2017 RESULTS: Metformin attenuates the effects of TNF-alpha on Caco-2 cell TEER and paracellular permeability, prevents TNF-alpha-induced morphological disruption of tight junctions, ameliorates the inhibiting effect of TNF-alpha on epithelial tight junction-related protein expression and suppresses the TNF-alpha-induced increase in MLCK production. Metformin 9-18 tumor necrosis factor Homo sapiens 115-124 29228440-7 2017 RESULTS: Metformin attenuates the effects of TNF-alpha on Caco-2 cell TEER and paracellular permeability, prevents TNF-alpha-induced morphological disruption of tight junctions, ameliorates the inhibiting effect of TNF-alpha on epithelial tight junction-related protein expression and suppresses the TNF-alpha-induced increase in MLCK production. Metformin 9-18 tumor necrosis factor Homo sapiens 115-124 29228440-7 2017 RESULTS: Metformin attenuates the effects of TNF-alpha on Caco-2 cell TEER and paracellular permeability, prevents TNF-alpha-induced morphological disruption of tight junctions, ameliorates the inhibiting effect of TNF-alpha on epithelial tight junction-related protein expression and suppresses the TNF-alpha-induced increase in MLCK production. Metformin 9-18 tumor necrosis factor Homo sapiens 115-124 27904616-7 2016 After folic acid and metformin administration, mean of Hcy, HOMA-IR, TNF-alpha, and IL-8 decreased significantly (P < 0.05). Metformin 21-30 tumor necrosis factor Homo sapiens 69-78 28410530-6 2017 Meanwhile, the suppressive effects of metformin on MPO, TNF-alpha, CK-MB and BNP were reversed by the AMPK inhibitor. Metformin 38-47 tumor necrosis factor Homo sapiens 56-65 28553078-9 2017 Levels of TNF-alpha, hs-CRP, and vaspin were reduced by metformin XR but not by the IR formulation. Metformin 56-65 tumor necrosis factor Homo sapiens 10-19 28157701-4 2017 Metformin treated cancer cells increased macrophage expression of M1-related cytokines IL-12 and TNF-alpha and attenuated M2-related cytokines IL-8, IL-10, and TGF-beta expression. Metformin 0-9 tumor necrosis factor Homo sapiens 97-106 28002460-12 2016 Consistently, in Caco-2 cells, metformin promoted claudin-3 and E-cadherin assembly and mitigated TNF-alpha-induced fragmentation of tight junction proteins. Metformin 31-40 tumor necrosis factor Homo sapiens 98-107 27893782-0 2016 Beneficial Effects of Metformin and/or Salicylate on Palmitate- or TNFalpha-Induced Neuroinflammatory Marker and Neuropeptide Gene Regulation in Immortalized NPY/AgRP Neurons. Metformin 22-31 tumor necrosis factor Homo sapiens 67-75 27893782-8 2016 We determined co-treatment with metformin or sodium salicylate alone was successful in alleviating changes observed in feeding peptide mRNA regulation, whereas a preventative pre-treatment with metformin and sodium salicylate together was able to alleviate palmitate- and TNFalpha-induced induction of NPY and/or AgRP mRNA levels. Metformin 194-203 tumor necrosis factor Homo sapiens 272-280 27904436-8 2016 Furthermore, compared to individual drug treatment, metformin significantly reduced the levels of serum IL-6 and TNF-alpha, as well as urine MCP-1. Metformin 52-61 tumor necrosis factor Homo sapiens 113-122 26305116-9 2016 Metformin can exert an anti-inflammatory effect by direct inhibition of IL-6, TNF-alpha, and VEGF. Metformin 0-9 tumor necrosis factor Homo sapiens 78-87 27619024-8 2016 Pretreatment of metformin dose dependently suppressed the expression of TNF-alpha mRNA induced by LPS (2 mM, p = 0.03). Metformin 16-25 tumor necrosis factor Homo sapiens 72-81 26963617-12 2016 In the SHR-CRP transgenic strain, we found that metformin treatment decreased circulating levels of inflammatory response marker IL-6, TNFalpha and MCP-1 while levels of human CRP remained unchanged. Metformin 48-57 tumor necrosis factor Homo sapiens 135-143 26930651-7 2016 In ex vivo studies, 100 muM of metformin decreased the TLR4 level by 19.9% (II group) or by 35% (III group) as well as IL-1beta and TNFalpha production. Metformin 31-40 tumor necrosis factor Homo sapiens 132-140 26896068-9 2016 Moreover, metformin enhanced the anti-inflammatory effect of 5-ASA by decreasing the gene expression of IL-1beta, IL-6, COX-2 and TNF-alpha and its receptors; TNF-R1 and TNF-R2. Metformin 10-19 tumor necrosis factor Homo sapiens 130-139 22688336-10 2012 TNFRI combined with the antidiabetic agent, metformin, improved DBD beyond that achieved with metformin alone, suggesting that therapies targeting TNF-alpha may have utility in reversing the secondary urologic complications of type 2 diabetes. Metformin 44-53 tumor necrosis factor Homo sapiens 147-156 26320144-10 2015 In addition, metformin reduced glucose, follicle-stimulating hormone, IL6 and TNFalpha levels and increased dehydroepiandrosterone sulfate levels. Metformin 13-22 tumor necrosis factor Homo sapiens 78-86 25889494-3 2015 METHODS: We evaluated the effects of 5-amino-imidazole-4-carboxyamide-1- beta-D-ribofuranoside (AICAR) and metformin on tumor necrosis factor (TNF)-alpha- stimulated chemokine production in human granulosa cells. Metformin 107-116 tumor necrosis factor Homo sapiens 120-153 25889494-5 2015 RESULTS: AICAR and metformin markedly reduced the IL-8 and GROalpha production induced by TNF-alpha. Metformin 19-28 tumor necrosis factor Homo sapiens 90-99 25889494-6 2015 AICAR and metformin also reduced the TNF-alpha-induced phosphorylation of I-kappaB. Metformin 10-19 tumor necrosis factor Homo sapiens 37-46 25889494-8 2015 CONCLUSIONS: These results suggest that metformin promotes granulosa cell function by reducing a TNF-alpha- and chemokine-mediated inflammatory reaction through an AMPK-dependent pathway. Metformin 40-49 tumor necrosis factor Homo sapiens 97-106 23677182-0 2012 [Effect of metformin on the expression of tumor necrosis factor-alpha, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients]. Metformin 11-20 tumor necrosis factor Homo sapiens 42-69 23677182-9 2012 Participants receiving metformin had lower levels of hsCRP and lower mRNA relative abundance of TNF-alpha and TLR 2/4. Metformin 23-32 tumor necrosis factor Homo sapiens 96-105 23677182-11 2012 CONCLUSIONS: Obese diabetic patients treated with metformin had lower levels of hsCRP expression of TNF-alpha and TLR 2/4, than their counterparts not receiving the drug. Metformin 50-59 tumor necrosis factor Homo sapiens 100-109 26141671-6 2015 In addition, treatment with metformin significantly reduced the expression of IL-6 and TNF-alpha at the messenger RNA level and attenuated nuclear factor kappa B (NF-kappaB) DNA binding activity in MNCs. Metformin 28-37 tumor necrosis factor Homo sapiens 87-96 25817233-11 2015 Co-treatment with metformin or AICAR decreased the TNF-alpha-induced intracellular TG, accompanied by significantly enhanced AMPK and ACC phosphorylation, suppressed mTOR and p70S6K phosphorylation, and reduced SREBP-1 and FAS expressions. Metformin 18-27 tumor necrosis factor Homo sapiens 51-60 25590211-0 2015 Metformin reverts the secretion of CXCL8 induced by TNF-alpha in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. Metformin 0-9 tumor necrosis factor Homo sapiens 52-61 25590211-4 2015 OBJECTIVE: This study aimed to evaluate whether metformin inhibits the secretion of CXCL8 induced by Tumor-Necrosis-Factor-alpha (TNF-alpha) in primary cultures of normal and tumor human thyroid cells as well as in thyroid cancer cell lines. Metformin 48-57 tumor necrosis factor Homo sapiens 101-128 25590211-4 2015 OBJECTIVE: This study aimed to evaluate whether metformin inhibits the secretion of CXCL8 induced by Tumor-Necrosis-Factor-alpha (TNF-alpha) in primary cultures of normal and tumor human thyroid cells as well as in thyroid cancer cell lines. Metformin 48-57 tumor necrosis factor Homo sapiens 130-139 25590211-7 2015 RESULTS: Metformin significantly and dose-dependently inhibited the TNF-alpha-induced CXCL8 secretion in both normal thyrocytes (ANOVA: F = 42.04; P < .0001) and papillary thyroid cancer cells (ANOVA: F = 21.691; P < .0001) but not in TPC-1 and BCPAP cell lines. Metformin 9-18 tumor necrosis factor Homo sapiens 68-77 25590211-8 2015 CONCLUSION: Metformin inhibits the TNF-alpha-induced CXCL8 secretion in primary cultures of normal thyroid cells and differentiated thyroid cancer cells at least of the most frequent poorly aggressive phenotype. Metformin 12-21 tumor necrosis factor Homo sapiens 35-44 25590211-10 2015 Thus, the here-reported inhibiting effect of metformin on TNF-alpha-induced CXCL8 secretion could be considered as a further indirect anticancer property of the drug. Metformin 45-54 tumor necrosis factor Homo sapiens 58-67 26120598-6 2015 Further investigation into the effects of metformin suggest that the drug directly activates AMPK and dose-dependently suppressed the release of TNF-alpha, IL-6, and MCP-1 by macrophages while enhancing the release of IL-10 in vitro. Metformin 42-51 tumor necrosis factor Homo sapiens 145-154 25560571-6 2015 A metformin combination therapy significantly decreased such inflamation parameters as hs-CRP, ox-LDL, TNF-alpha and IL-1beta levels relative to monotherapies. Metformin 2-11 tumor necrosis factor Homo sapiens 103-112 23659985-12 2013 Finally, metformin dose-dependently reduced TNF-alpha-induced IL-6 and IkappaBalpha levels in cultured placental JAR cells. Metformin 9-18 tumor necrosis factor Homo sapiens 44-53 23611575-2 2013 The administration of metformin reduced pain intensity from 9/10 to 3/10 and favorably affected the profile of inflammatory cytokines (i.e., TNF a, IL-1beta, IL-6, and IL-10), adipokines (i.e., adiponectin, leptin, and resistin), and beta-endorphin. Metformin 22-31 tumor necrosis factor Homo sapiens 141-146 22841520-5 2013 RESULTS: Compared to placebo, metformin reduced monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, monocyte chemoattractant protein-1 and interleukin-8, as well as decreased plasma C-reactive protein levels, which were accompanied by an improvement in insulin sensitivity. Metformin 30-39 tumor necrosis factor Homo sapiens 68-95 21424914-9 2011 In the metformin group, body mass index, PPG, HbA1c, IL-6, ICAM-1, and TNF-alpha levels were significantly decreased after 12 weeks compared with the basal levels. Metformin 7-16 tumor necrosis factor Homo sapiens 71-80 22570949-7 2012 In the metformin group, significant reductions were found in the variances of serum TNFalpha concentrations (p=0.006; Levene test). Metformin 7-16 tumor necrosis factor Homo sapiens 84-92 23091851-8 2012 The CHD and MS patients who carried the Pro allele showed a significant metformin-induced reduction in weight, waist circumference, body mass index, and concentrations of TC, C-peptide, and cytokines, such IL-1beta, IL-6, IL-8, and TNF-alpha. Metformin 72-81 tumor necrosis factor Homo sapiens 232-241 21954641-1 2011 The use of metformin during the first month of treatment of patients with coronary artery disease and diabetes type 2 led to the decrease of insulin resistance and reduced activity of systemic inflammation (significant decrease in the concentrations of IL-1, IL-6, IL-8 and TNF-alpha). Metformin 11-20 tumor necrosis factor Homo sapiens 274-283 21740847-10 2011 Metformin also increased phosphorylation of AMPK and eNOS, and reduced the expression of TGF-beta1, basic fibroblast growth factor (bFGF), and tumor necrosis factor (TNF)-alpha. Metformin 0-9 tumor necrosis factor Homo sapiens 143-176 22673924-1 2011 OBJECTIVE: The aim of the study was to determine whether metformin or vitamin E treatment for six months is effective in reducing body weight, blood pressure, and also ameliorating insulin resistance, adiponectin, and tumor necrosis factor (TNF)-alpha in obese adolescents with non-alcoholic fatty liver disease (NAFLD). Metformin 57-66 tumor necrosis factor Homo sapiens 218-251 21338323-5 2011 Pre-incubation with metformin (24 h, 1 mM) inhibited forskolin-, isoproterenol-, IBMX-, LPS-, IL-1beta- and TNF-alpha-induced glycerol release and prevented p(Ser554)HSL decrease and p(Ser-552)HSL increase due to lipolytic and inflammatory agents. Metformin 20-29 tumor necrosis factor Homo sapiens 108-117 20034685-8 2011 In addition, combined treatment with atorvastatin and metformin reduces the post-glucose loading levels of TNF-alpha compared to metformin monotherapy. Metformin 54-63 tumor necrosis factor Homo sapiens 107-116 20034685-8 2011 In addition, combined treatment with atorvastatin and metformin reduces the post-glucose loading levels of TNF-alpha compared to metformin monotherapy. Metformin 129-138 tumor necrosis factor Homo sapiens 107-116 9288574-0 1997 Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Metformin 17-26 tumor necrosis factor Homo sapiens 65-92 20371705-5 2010 Metformin significantly inhibited both TNF production and TF expression in isolated human monocytes stimulated with LPS or oxLDL. Metformin 0-9 tumor necrosis factor Homo sapiens 39-42 20371705-6 2010 Metformin also significantly inhibited TNF and TF mRNA in human monocytes stimulated with LPS. Metformin 0-9 tumor necrosis factor Homo sapiens 39-42 20371705-8 2010 These results suggest that metformin may attenuate the inflammatory responses, at least in part, by suppressing the production of both TNF and TF through the inhibition of the ERK1/2-Egr-1 pathway in human monocytes. Metformin 27-36 tumor necrosis factor Homo sapiens 135-138 20015525-8 2010 There were no significant variations of ADN, R, or TNF-alpha with sitagliptin, whereas a significant increase of ADN and a significant decrease of R and TNF-alpha values were recorded with metformin. Metformin 189-198 tumor necrosis factor Homo sapiens 153-162 20015525-10 2010 There was a significant correlation between HOMA-IR decrease and ADN increase, and between HOMA-IR decrease and R and TNF-alpha decrease in pioglitazone plus metformin group after the treatment. Metformin 158-167 tumor necrosis factor Homo sapiens 118-127 18082089-7 2007 Pharmacological treatment with either rosuvastatin or metformin lead to reductions in IL-6, TNFalpha, GSH and GPx levels and an increase in the SOD level, and there were significant interactions between the two treatment groups for these variables. Metformin 54-63 tumor necrosis factor Homo sapiens 92-100 16636195-5 2006 Metformin also dose-dependently inhibited tumor necrosis factor (TNF)-alpha-induced NF-kappaB activation and TNF-alpha-induced IkappaB kinase activity. Metformin 0-9 tumor necrosis factor Homo sapiens 42-75 16636195-5 2006 Metformin also dose-dependently inhibited tumor necrosis factor (TNF)-alpha-induced NF-kappaB activation and TNF-alpha-induced IkappaB kinase activity. Metformin 0-9 tumor necrosis factor Homo sapiens 109-118 16636195-6 2006 Furthermore, metformin attenuated the TNF-alpha-induced gene expression of various proinflammatory and cell adhesion molecules, such as vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1, in HUVECs. Metformin 13-22 tumor necrosis factor Homo sapiens 38-47 16636195-9 2006 The small interfering RNA for AMPKalpha1 attenuated metformin or AICAR-induced inhibition of NF-kappaB activation by TNF-alpha, suggesting a possible role of AMPK in the regulation of cell inflammation. Metformin 52-61 tumor necrosis factor Homo sapiens 117-126 15690319-0 2005 Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin. Metformin 93-102 tumor necrosis factor Homo sapiens 46-73 9505147-4 1998 The present investigation was undertaken to clarify whether metformin affects TNF-alpha and soluble TNF receptor levels. Metformin 60-69 tumor necrosis factor Homo sapiens 78-87 9505147-7 1998 Twelve weeks of metformin treatment increased TNF-alpha by 33% (P < 0.05). Metformin 16-25 tumor necrosis factor Homo sapiens 46-55 20371705-0 2010 Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. Metformin 0-9 tumor necrosis factor Homo sapiens 63-84 19494326-3 2009 We provide evidence that metformin attenuates the induction of EAE by restricting the infiltration of mononuclear cells into the CNS, down-regulating the expression of proinflammatory cytokines (IFN-gamma, TNF-alpha, IL-6, IL-17, and inducible NO synthase (iNOS)), cell adhesion molecules, matrix metalloproteinase 9, and chemokine (RANTES). Metformin 25-34 tumor necrosis factor Homo sapiens 206-215 18597869-0 2009 Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Metformin 0-9 tumor necrosis factor Homo sapiens 19-28 18597869-4 2009 The effects of metformin on TNF-alpha-induced IL-6 production were investigated. Metformin 15-24 tumor necrosis factor Homo sapiens 28-37 18597869-7 2009 Pre-treatment with metformin (100-1000 micromol/L) also inhibited TNF-alpha-induced IL-6 production, phosphorylation of IkappaB kinase (IKK) alpha/beta and IkappaB-alpha degradation. Metformin 19-28 tumor necrosis factor Homo sapiens 66-75 18597869-8 2009 Metformin increased phosphorylation of AMP-activated kinase (AMPK) but wortmannin, a PI3K inhibitor, negated its effects on AMPK phosphorylation and TNF-alpha-induced IkappaB-alpha degradation. Metformin 0-9 tumor necrosis factor Homo sapiens 149-158 18597869-10 2009 Transfection of siRNA against alpha1-AMPK eradicated the inhibitory effects of metformin on TNF-alpha-induced IL-6, implying the essential role of AMPK. Metformin 79-88 tumor necrosis factor Homo sapiens 92-101 18597869-11 2009 CONCLUSIONS: Metformin had anti-inflammatory effects on endothelial cells and inhibited TNF-alpha-induced IKKalpha/beta phosphorylation, IkappaB-alpha degradation and IL-6 production in HUVEC. Metformin 13-22 tumor necrosis factor Homo sapiens 88-97 11523631-3 2001 In past experiments, we used both labeled glucose uptake, lipogenesis, and stimulation of calmodulin gene expression to quantify the ability of the antidiabetic drugs (pioglitazone and metformin) to reverse tumor necrosis factor-alpha (TNF-alpha)-induced IR in these insulin-treated cells. Metformin 185-194 tumor necrosis factor Homo sapiens 207-234 11523631-3 2001 In past experiments, we used both labeled glucose uptake, lipogenesis, and stimulation of calmodulin gene expression to quantify the ability of the antidiabetic drugs (pioglitazone and metformin) to reverse tumor necrosis factor-alpha (TNF-alpha)-induced IR in these insulin-treated cells. Metformin 185-194 tumor necrosis factor Homo sapiens 236-245 9288574-3 1997 With TNF-alpha concentration at 1 ng/ml and 10(4) muU/ml INS, metformin 10 microM and pioglitazone 1.5 microM, reversed the IR induced by TNF-alpha restoring biologic response to 100% of INS effect alone. Metformin 62-71 tumor necrosis factor Homo sapiens 5-14 9288574-3 1997 With TNF-alpha concentration at 1 ng/ml and 10(4) muU/ml INS, metformin 10 microM and pioglitazone 1.5 microM, reversed the IR induced by TNF-alpha restoring biologic response to 100% of INS effect alone. Metformin 62-71 tumor necrosis factor Homo sapiens 138-147 34611097-0 2021 Metformin Inhibits Transforming Growth Factor beta-Induced Fibrogenic Response of Human Dermal Fibroblasts and Suppresses Fibrosis in Keloid Spheroids. Metformin 0-9 tumor necrosis factor Homo sapiens 19-50 34763093-8 2021 Moreover, metformin suppressed LL37- and TNF-alpha-induced the ROS production and MAPK-NF-kappaB signal activation in keratinocytes cells. Metformin 10-19 tumor necrosis factor Homo sapiens 41-50 34670977-0 2021 Metformin Inhibits Transforming Growth Factor beta-Induced Fibrogenic Response of Human Dermal Fibroblasts and Suppresses Fibrosis in Keloid Spheroids. Metformin 0-9 tumor necrosis factor Homo sapiens 19-50 33798839-7 2021 Metformin exposure was also associated with decreased levels of the inflammatory cytokines TNFalpha, IL-1a, IL-1b and IL-6 in serum, placenta and omental tissue taken from pregnant women. Metformin 0-9 tumor necrosis factor Homo sapiens 91-99 34717078-8 2021 Additionally, the meta-analysis revealed that circulating tumor necrosis factor-alpha(TNF-alpha) and C-reactive protein (CRP) concentrations were significantly decreased after metformin treatment, with corresponding SMDs of 1.01 (95% CI: 0.74-1.28, P<0.00001) and 0.48(95% CI: 0.35-0.60, P<0.00001). Metformin 176-185 tumor necrosis factor Homo sapiens 58-85 34717078-8 2021 Additionally, the meta-analysis revealed that circulating tumor necrosis factor-alpha(TNF-alpha) and C-reactive protein (CRP) concentrations were significantly decreased after metformin treatment, with corresponding SMDs of 1.01 (95% CI: 0.74-1.28, P<0.00001) and 0.48(95% CI: 0.35-0.60, P<0.00001). Metformin 176-185 tumor necrosis factor Homo sapiens 86-95 34850313-0 2022 Metformin effect in models of inflammation is associated with activation of ATP-dependent potassium channels and inhibition of tumor necrosis factor-alpha production. Metformin 0-9 tumor necrosis factor Homo sapiens 127-154 34850313-9 2022 Metformin (1000 mg/kg) reduced the production of tumor necrosis factor-alpha induced by i.pl. Metformin 0-9 tumor necrosis factor Homo sapiens 49-76 34277866-12 2021 Results: Photobiomodulation at 1, 2, and 3 J/cm2 combined with metformin significantly promoted diabetic cell lines of HPDLSCs viability (in MTT assay and ELISA reader of ROS, TNF-alpha, IL-10 results) and gene expression of Nrf2, Keap1, PIK3, and HO-1 levels (p< 0.05). Metformin 63-72 tumor necrosis factor Homo sapiens 176-185 34284806-12 2021 Metformin promoted SFRP5 and decreased leptin, IL-6 and TNFalpha secretion in PCOS women with metabolic abnormality in a time dependent manner and with improved ovulation rate and pregnancy rate. Metformin 0-9 tumor necrosis factor Homo sapiens 56-64 35605453-10 2022 In addition, there was an increase in the serum levels of TNFalpha and IL-6 in type 2 diabetic patients and this was reversed with metformin treatment. Metformin 131-140 tumor necrosis factor Homo sapiens 58-66